Is olanzapine (olanzapine) a one-to-one conversion from intravenous (IV) to oral (PO)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Olanzapine IV to PO Conversion

Olanzapine has a one-to-one conversion ratio between intravenous (IV) and oral (PO) administration. This is evident from the National Comprehensive Cancer Network (NCCN) guidelines which consistently list the same 10 mg dose for olanzapine regardless of whether it's administered orally or intravenously in antiemetic regimens 1.

Evidence Supporting 1:1 Conversion

The NCCN Antiemesis Guidelines (2017) clearly demonstrate the equivalent dosing between IV and PO olanzapine:

  • In antiemetic regimens for highly emetogenic chemotherapy, olanzapine is dosed at 10 mg whether given orally or intravenously 1
  • When olanzapine is used in combination with palonosetron and dexamethasone, the olanzapine dose remains consistent at 10 mg regardless of route of administration 1

Clinical Applications

Antiemetic Use

  • For chemotherapy-induced nausea and vomiting, olanzapine is administered at 10 mg PO once daily for 3-4 days 1
  • When transitioning from IV to PO in this setting, the same 10 mg dose is maintained 1

Psychiatric Use

  • In the management of acute agitation in schizophrenia, studies have shown successful transition from IM olanzapine 10 mg to oral olanzapine 5-20 mg/day without dosage adjustment 2
  • A retrospective study examining IV olanzapine administration in emergency departments used the same dosing ranges for IV as typically used for oral administration (2.5 mg, 5 mg) 3

Safety Considerations

When administering olanzapine intravenously:

  • Hypotension may occur in approximately 5.2% of administrations 4
  • Bradycardia has been reported in about 1.3% of IV administrations 4
  • Phlebitis is rare (1.4% of administrations) 4
  • Respiratory depression should be monitored, particularly when combined with other sedative medications 3

Important Caveats

  • While the evidence supports a 1:1 conversion ratio, individual patient factors should be considered:

    • Smoking status can decrease olanzapine levels through CYP1A2 induction 5
    • Drug interactions, particularly with CYP1A2 inhibitors like fluvoxamine, can increase olanzapine concentrations 5
    • Elderly patients may require lower doses due to decreased clearance 5
  • The optimal therapeutic range for olanzapine serum levels is 20-40 ng/mL, with concentrations above 80 ng/mL associated with increased adverse events 5

  • Unlike some other medications that require dosage adjustments when changing routes (such as certain opioids that use a 2:1 or 3:1 oral-to-parenteral ratio), olanzapine maintains its potency across different routes of administration 6

Bottom Line

When transitioning patients between IV and PO olanzapine, maintain the same dose. The pharmacokinetic properties of olanzapine allow for this straightforward 1:1 conversion, making it simpler to manage compared to medications requiring complex conversion calculations.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2016

Research

[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].

Fortschritte der Neurologie-Psychiatrie, 2001

Guideline

Pain Management with Opioids

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.